Illinois Lands $1.5 Billion Investment from CSL for New Biotherapeutics Facility

Expansion will create 300 new jobs and retain over 1,200 existing positions at Kankakee campus

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Governor JB Pritzker and the Illinois Department of Commerce and Economic Opportunity announced that global biotherapeutics leader CSL will invest nearly $1.5 billion to construct a new manufacturing facility at the company's Kankakee campus, creating 300 new full-time jobs while retaining more than 1,200 existing positions. CSL's investment marks one of the largest life sciences investments in Illinois history, reinforcing the state's leadership in the industry.

Why it matters

This expansion by CSL underscores Illinois' position as a hub for life sciences manufacturing and innovation. The new facility will strengthen the state's biotherapeutics supply chain and ensure patients have reliable access to critical plasma-derived therapies produced in Illinois.

The details

CSL will expand their current footprint in Illinois by constructing a new state-of-the-art manufacturing facility at their Kankakee campus to increase production capacity for the company's top immunoglobulin therapies, Privigen and Hizentra. For the first time, this project will bring the company's full manufacturing process—from plasma collection through filling and packing—entirely to the U.S., while positioning the Illinois facility to supply 100% of its U.S. demand for immunoglobulin therapies.

  • The expansion announcement was made on March 9, 2026.

The players

Governor JB Pritzker

The Governor of Illinois who announced the CSL investment.

CSL

A global biotherapeutics leader that is investing $1.5 billion to expand its manufacturing facility in Kankakee, Illinois.

Kristin Richards

The Director of the Illinois Department of Commerce and Economic Opportunity.

Christy George

The President and CEO of the Illinois Economic Development Corporation.

Gil Quiniones

The President and CEO of ComEd.

Got photos? Submit your photos here. ›

What they’re saying

“Illinois is leading the way in life sciences manufacturing, and CSL's $1.5 billion investment is a powerful vote of confidence in our state. This expansion will create hundreds of good-paying jobs and strengthen domestic supply chains for critical therapies.”

— Governor JB Pritzker (riverbender.com)

“Behind every plasma-derived therapy is a person trying to live a more stable life, and a donor who made that therapy possible. As the need for plasma-derived therapies continues to grow in the U.S. and globally, expanding our Kankakee site further strengthens this key hub in our supply network.”

— Gordon Naylor, Interim Chief Executive Officer and Managing Director, CSL (riverbender.com)

“This site expansion marks an important step forward in increasing efficiency by incorporating new, innovative manufacturing processes and technology into how we produce the plasma-based medicines needed by so many people.”

— Mary Oates, CSL Executive Vice President and Chief Operating Officer (riverbender.com)

What’s next

The state is finalizing an Economic Development for a Growing Economy (EDGE) agreement with CSL to support the expansion project.

The takeaway

This major investment by CSL solidifies Illinois' position as a leading hub for life sciences manufacturing and innovation. The new facility will strengthen the state's biotherapeutics supply chain and create hundreds of good-paying jobs, underscoring Illinois' commitment to supporting the growth of cutting-edge industries.